These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

190 related items for PubMed ID: 6433044

  • 1. Prevention of cyclophosphamide cystitis with 2-mercaptoethane sodium sulfonate: a histologic study.
    Freedman A, Ehrlich RM, Ljung BM.
    J Urol; 1984 Sep; 132(3):580-2. PubMed ID: 6433044
    [Abstract] [Full Text] [Related]

  • 2. The use of sodium 2-mercaptoethane sulfonate to prevent cyclophosphamide cystitis.
    Ehrlich RM, Freedman A, Goldsobel AB, Stiehm ER.
    J Urol; 1984 May; 131(5):960-2. PubMed ID: 6423841
    [Abstract] [Full Text] [Related]

  • 3. Prevention of urinary bladder tumors in cyclophosphamide-treated rats by additional medication with the uroprotectors sodium 2-mercaptoethane sulfonate (mesna) and disodium 2,2'-dithio-bis-ethane sulfonate (dimesna).
    Habs MR, Schmähl D.
    Cancer; 1983 Feb 15; 51(4):606-9. PubMed ID: 6401591
    [Abstract] [Full Text] [Related]

  • 4. Effect of the uroprotector sodium 2-mercaptoethane sulfonate (Mesna) on the proliferation of the bladder urothelium in the rat after administration of cyclophosphamide.
    Kunze E, Köhnecke B, Engelhardt W, Steinröder H, Brock N, Pohl J.
    Urol Int; 1984 Feb 15; 39(2):61-7. PubMed ID: 6426112
    [Abstract] [Full Text] [Related]

  • 5. Contribution of flavonoid antioxidants to the preventive effect of mesna in cyclophosphamide-induced cystitis in rats.
    Ozcan A, Korkmaz A, Oter S, Coskun O.
    Arch Toxicol; 2005 Aug 15; 79(8):461-5. PubMed ID: 15800758
    [Abstract] [Full Text] [Related]

  • 6. Cyclophosphamide-induced Down-Regulation of Uroplakin II in the Mouse Urinary Bladder Epithelium is Prevented by S-Allyl Cysteine.
    Abdi SA, Najmi AK, Raisuddin S.
    Basic Clin Pharmacol Toxicol; 2016 Dec 15; 119(6):598-603. PubMed ID: 27234646
    [Abstract] [Full Text] [Related]

  • 7. [Prevention of tumor formation in the bladder by sodium-2-mercaptoethane sulfonate (mesna). Experimental studies and clinical consequences].
    Schmähl D, Habs M, Tacchi AM.
    Urologe A; 1984 Sep 15; 23(5):291-6. PubMed ID: 6438859
    [Abstract] [Full Text] [Related]

  • 8. The efficacy of mesna (2-mercaptoethane sodium sulfonate) as a uroprotectant in patients with hemorrhagic cystitis receiving further oxazaphosphorine chemotherapy.
    Andriole GL, Sandlund JT, Miser JS, Arasi V, Linehan M, Magrath IT.
    J Clin Oncol; 1987 May 15; 5(5):799-803. PubMed ID: 3106585
    [Abstract] [Full Text] [Related]

  • 9. The prevention of cyclophosphamide-induced bladder swelling in the rat by I.V. administration of sodium-2-mercaptoethane sulfonate.
    Kedar A, Simpson CL, Williams P, Moore R, Tritsch G, Murphy GP.
    Res Commun Chem Pathol Pharmacol; 1980 Aug 15; 29(2):339-48. PubMed ID: 6774389
    [Abstract] [Full Text] [Related]

  • 10. [Effects of mesna (2-mercaptoethane sodium sulfonate) in children with malignant disease receiving oxazaphosphorine chemotherapy].
    Iwasaku-Fujimoto M, Fujiwara F, Todo S, Morioka Y, Imashuku S.
    Gan To Kagaku Ryoho; 1990 Mar 15; 17(3 Pt 1):403-6. PubMed ID: 2106836
    [Abstract] [Full Text] [Related]

  • 11. [Usefulness of 2-mercaptoethanol sodium sulfonate (Mesnum) in the prevention of hemorrhagic cystitis in patients undergoing bone marrow transplantation].
    Grañena A, Gardella S, Marín P, Carreras E, Montserrat E, Rozman C.
    Sangre (Barc); 1986 Mar 15; 31(3):307-10. PubMed ID: 3092373
    [No Abstract] [Full Text] [Related]

  • 12. Efficacy of mesna in preventing further cyclophosphamide-induced hemorrhagic cystitis.
    Luce JK, Simons JA.
    Med Pediatr Oncol; 1988 Mar 15; 16(6):372-4. PubMed ID: 3143903
    [Abstract] [Full Text] [Related]

  • 13. Bone marrow transplantation for Wiskott-Aldrich syndrome: report of 2 cases with use of 2-mercaptoethane sulfonate.
    Goldsobel AB, Ehrlich RM, Mendoza GR, Stiehm ER.
    Transplantation; 1985 May 15; 39(5):568-70. PubMed ID: 3922097
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Comparison of reduced glutathione with 2-mercaptoethane sulfonate to prevent cyclophosphamide-induced urotoxicity.
    Cavalletti E, Tofanetti O, Zunino F.
    Cancer Lett; 1986 Jul 15; 32(1):1-6. PubMed ID: 3091245
    [Abstract] [Full Text] [Related]

  • 16. Electron microscopic investigations of the cyclophosphamide-induced lesions of the urinary bladder of the rat and their prevention by mesna.
    Themann H, Oberdorf E, Brock N, Pohl J.
    Urol Int; 1987 Jul 15; 42(1):37-43. PubMed ID: 3109094
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Mesna versus forced diuresis to prevent cyclophosphamide induced haemorrhagic cystitis in marrow transplant patients (preliminary data).
    Hows J, Mehta A, Gordon-Smith EC.
    Cancer Treat Rev; 1983 Sep 15; 10 Suppl A():53-6. PubMed ID: 6414696
    [No Abstract] [Full Text] [Related]

  • 20. [Evaluation of the benefits of sodium 2-mercaptoethane sulfonate (MESNA) therapy for children undergoing high-dose chemotherapy].
    Sato J, Takaue Y, Saito S, Okamoto Y, Hirao A, Shimizu T, Abe T, Watanabe T, Kawano Y, Ninomiya T.
    Rinsho Ketsueki; 1993 Jan 15; 34(1):7-12. PubMed ID: 8450612
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.